The place of tumor necrosis factor alpha inhibitors in the treatment of rheumatoid arthritis patients: tactics in different variants of the disease
As the period of use of genetically engineered biologic drugs (GEBD) in clinical practice is growing, clinicians are faced with new questions: how to switch from one GEBD to another in case of primary or secondary inefficacy, intolerance to previous GEBD therapy; what should be done after low diseas...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2015-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/180 |
| Summary: | As the period of use of genetically engineered biologic drugs (GEBD) in clinical practice is growing, clinicians are faced with new questions: how to switch from one GEBD to another in case of primary or secondary inefficacy, intolerance to previous GEBD therapy; what should be done after low disease activity or remission is achieved. The article highlights the recent findings that are relevant for healthcare practitioners. |
|---|---|
| ISSN: | 2079-701X 2658-5790 |